News
Study into prophylaxis treatment meets key endpoints
Sanofi and Swedish Orphan Biovitrum AB have announced positive results from the pivotal XTEND-1 phase 3 study into efanesoctocog alfa (BIVV001).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Sanofi and Swedish Orphan Biovitrum AB have announced positive results from the pivotal XTEND-1 phase 3 study into efanesoctocog alfa (BIVV001).